BCAL Diagnostics Limited (ASX:BDX – Get Free Report) insider Jayne Shaw acquired 725,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average cost of A$0.11 ($0.07) per share, for a total transaction of A$76,850.00 ($50,894.04).
BCAL Diagnostics Price Performance
The company has a quick ratio of 6.70, a current ratio of 5.21 and a debt-to-equity ratio of 24.77.
BCAL Diagnostics Company Profile
Want More Great Investing Ideas?
Featured Articles
- Five stocks we like better than BCAL Diagnostics
- Breakout Stocks: What They Are and How to Identify Them
- Costco Split History: Is it Time for Costco to Split Again?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Signet Jewelers Stock Poised for Rebound After Earnings Drop
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Airship AI Lands New Contract: Stock Soars 16% and More to Come
Receive News & Ratings for BCAL Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BCAL Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.